{"id":148,"date":"2024-10-31T10:00:00","date_gmt":"2024-10-31T10:00:00","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=148"},"modified":"2025-09-02T08:01:49","modified_gmt":"2025-09-02T08:01:49","slug":"china-bd-2024-regor-and-genentech-roche-enters-a-license-on-two-cdk-inhibitor-programs","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2024\/148.html","title":{"rendered":"[China BD 2024] Regor and Genentech (Roche) enters a license on two CDK inhibitor programs"},"content":{"rendered":"\n<p>Announced Date: 2024-9-30 (September 30, 2024)<\/p>\n\n\n\n<p>Asset Name: RGT-419B(GDC-4198) and\u00a0RGT-587(GDC-0587)<\/p>\n\n\n\n<p>Licensor: Regor Pharmaceuticals (China)<\/p>\n\n\n\n<p>Licensee (Buyer):  Genentech, a member of the Roche Group<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Asset Modality: Small Molecule<\/p>\n\n\n\n<p>Asset Target: CDK inhibitors<\/p>\n\n\n\n<p>Potential Indication:  breast cancer<\/p>\n\n\n\n<p>Current Stage: Phase 1<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Scope of Authority: &nbsp;<\/p>\n\n\n\n<p>Genentech\u00a0will acquire Regor&#8217;s next-generation CDK inhibitors.<\/p>\n\n\n\n<p>Genentech will be responsible for clinical development, manufacturing and commercialization worldwide. <\/p>\n\n\n\n<p>Regor will continue to manage the two ongoing Phase 1 trials to their completion.<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Deal Detail:<\/p>\n\n\n\n<p>Upfront payment of $850 million,<\/p>\n\n\n\n<p>Milestone payments, undisclosed.<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Link:<\/p>\n\n\n\n<p><a href=\"https:\/\/regor.com\/\">https:\/\/regor.com\/<\/a><\/p>\n\n\n\n<p><a href=\"https:\/\/www.prnewswire.com\/news-releases\/regor-enters-into-a-definitive-purchase-agreement-for-genentech-to-acquire-regors-portfolio-of-next-generation-cdk-inhibitors-for-the-treatment-of-breast-cancer-302262174.html\">Regor Enters into a Definitive Purchase Agreement for Genentech to Acquire Regor&#8217;s Portfolio of next-generation CDK inhibitors for the Treatment of Breast Cancer (prnewswire.com)<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Announced Date: 2024-9-30 (September 30, 2024) Asset Name: RGT-419B(GDC-4198) and\u00a0RGT-587(GDC-0587) Licensor: Regor Pharmaceuticals (China) Licensee (Buyer): &hellip; <a title=\"[China BD 2024] Regor and Genentech (Roche) enters a license on two CDK inhibitor programs\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2024\/148.html\"><span class=\"screen-reader-text\">[China BD 2024] Regor and Genentech (Roche) enters a license on two CDK inhibitor programs<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-148","post","type-post","status-publish","format-standard","hentry","category-china-license-out"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/148","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=148"}],"version-history":[{"count":1,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/148\/revisions"}],"predecessor-version":[{"id":149,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/148\/revisions\/149"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=148"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=148"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=148"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}